Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Genital Diseases, Male 1Endometrial Neoplasms 1

Interventions

darolutamide 2olaparib 1gedatolisib 1gallium 68 PSMA-11 1Surveys and Questionnaires 1Radiotherapy 1Prostate-Specific Antigen 1Pluvicto 1Nivolumab 1Lutetium-177 1Lutetium 1Cryotherapy 1Brachytherapy 1Androgen Antagonists 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Diseases × gedatolisib × 1 year × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡